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The research in the area of one-pot chemoenzymatic cascades is rapidly progressing. 
However, most of the biocatalysts currently involved in this field are pure enzymes, while 
whole cells and crude enzyme extracts remain unexplored. The main goal of this work is the 
development of a chemo-biocatalytic one-pot two-step system involving whole cell 
monoamine oxidase (MAO) coupled with a Cu-based oxidative system (CuI/H2O2) for the 
transformation of 1,2,3,4-tetrahydroisoquinoline (THIQ) to 3,4-dihydroisoquinolin-1(2H)-
one (DHIO). For the biological oxidative step, MAO-N variants D9 and D11 were tested in 
the form of whole cell and crude lysate biocatalysts. Among these, whole E. coli 
OverExpress C43(DE3) cells expressing MAO-N D9 with the following kinetic parameters –  
Vmax = 36.58 mM/h, KM = 8.124 mM – showed the best performance and were employed in 
combination with the chemical catalysis step in a sequential one-pot two-step process. A 
stepwise feeding strategy was applied to produce the intermediate 3,4-dihydroisoquinoline 
(DHIQ). The biotransformation was scaled-up to the initial volume of 25 ml and after triple 
THIQ feeding, 48.2 mM DHIQ was reached with a yield of 71.3%. At this stage, chemical 
catalysts (1 mol% CuI and 10 eq. H2O2) were added to the biologically produced DHIQ, 
which was transformed to ~30 mM DHIO at a 69.4% overall yield. As MAO-N variants have 
wide substrate specificity, this work broadens the portfolio of one-pot chemoenzymatic 
processes employing whole cell biocatalysts, representing an alternative to using pure 
enzymes.  
 





The idea of combining enzymes with suitable chemical catalysts in one-pot reactions has 
been a focus of researchers to a large extent over the past 10 years as one of the tools for 
producing interesting and valuable substances under mild conditions. One-pot processes 
benefit from the fact that usually there is no need for intermediate recovery, purification steps 
and the use of protective groups or reagents (Schoevaart and Kieboom 2002); therefore, 
several operational steps are omitted. In the pioneering work in this field, glucose isomerase 
was combined with a heterogeneous platinum catalyst for the one-pot conversion of a mixture 
of D-glucose and D-fructose into D-mannitol in aqueous conditions. It was the first time the 
compatibility of chemo- and biocatalysis was demonstrated in a tandem one-pot process 
(Makkee et al. 1980). Biocatalysis is, nowadays, a partner, rather than a rival of the 
chemocatalysts. Since biocatalysts usually operate in aqueous environments, and thus 
contribute to replacing organic solvents, applying enzymes and whole cells to particular 
chemical processes might reduce their E-factors, which represent the environmental 
compatibility and complexity of the synthesis (Woodley 2008). Gröger and Hummel (2014) 
reviewed the currently-known one-pot processes in aqueous medium, combining 
metal/organocatalysis with biocatalysis. Although tandem and sequential one-pot reactions 
with bio- and chemocatalysts broaden the portfolio of organic synthesis, it is noteworthy to 
say that whole cells are rather an exception (Ema et al. 2008; Fuchs et al. 2011; Liu et al. 
2009; Szymanski et al. 2010) and mostly free enzymes have been involved in these processes. 
However, whole cells are used in 75% of industrially implemented redox biotransformations, 
when often cofactor regeneration is necessary and/or the enzyme is not stable outside the cell. 
Generally, whenever whole cells can be used, the process is economically more attractive 
compared to the use of isolated enzymes (Carballeira et al. 2009; Solano et al. 2012).  
Enantioselective recombinant mutants of monoamine oxidase MAO-N have been derived 
from the same wild-type sequence by directed evolution combined with rational design and 
high-throughput screening methods (Ghislieri et al. 2013a; 2013b; Heath et al. 2014; Turner 
2009; Turner 2011). By deracemization of a broad range of amine substrates facilitated by 
MAO-N, a variety of intermediates and structure motifs for the pharmaceutical and 
agrochemical industries are produced, including boceprevir for the treatment of hepatitis C  
(Li et al. 2012). The production of chiral amines from racemic mixtures of primary (Alexeeva 
et al. 2002), secondary (Carr et al. 2003) and tertiary (Dunsmore et al. 2006) amines is 
performed as a one-pot chemo-biocatalysed reaction involving MAO-N for the 
stereoselective oxidative step and usually amine borane complex as the non-specific reducing 
agent, although recently a new way for deracemization has been proposed by combining 
amine oxidase and imine reductase enabling one-pot process performance (Heath et al. 2016). 
The MAO-N variants D9 and D11 differ by a single point mutation (H430G), which results in 
the increased active site volume of the D11 variant, allowing for the binding of sterically 
demanding substrates (Ghislieri et al. 2013a; 2013b).  
1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones were identified as 
potent and selective inhibitors of Kinase insert Domain containing Receptor (KDR). Small 
molecules inhibiting KDR kinase activity might prospectively be used in the clinic to treat 
human tumors (Choquette et al. 2008).  
The aim of this work is to develop a one-pot chemo-biocatalytic transformation of the amine 
1,2,3,4-tetrahydroisoquiniline to the lactam 3,4-dihydroisoquinoline-1(2H)-one using whole 
cells expressing MAO-N in combination with CuI/H2O2 in order to produce a structure 
pattern that might potentially be further used in the synthesis of KDR inhibitors. 
  
 
MATERIALS AND METHODS 
 
Microorganisms  
Monoamine oxidase mutants MAO-N D9 and MAO-N D11, harbored in plasmid pET16b, 
were developed and kindly provided by the team of Prof. Nicholas Turner (Manchester 
Institute of Biotechnology, University of Manchester, UK). The plasmids were transformed 
to three different E. coli strains of chemically competent cells: BL21(DE3) Gold (Stratagene, 
NL), Lemo21(DE3) (New England Biolabs, CA) and OverExpress C43(DE3) (Lucigen, 
USA), according to manufacturers´ protocols. Preliminary small-scale expression studies to 
select the best strain for MAO-N expression were performed according to the manufacturers´ 
recommendations, followed by SDS-PAGE detection of protein expression and activity 
testing (section Biotransformation). Protein quantification was carried out using the Bradford 
method with bovine serum albumin as a standard.  
 
Biomass production and expression of MAO-N 
Unless stated otherwise, all chemicals were purchased from Sigma Aldrich and the solvents 
were of HPLC grade. Besides the small-scale preliminary expression studies, larger cell 
batches (especially of E. coli OverExpress C43(DE3)) were produced in an autoinduction 
medium according to Schrittwieser et al. (2014) procedures. The stock solutions were 
sterilised separately and were mixed to get the proper composition of the medium prior to 
inoculation. The inoculum was prepared in LB medium (10 g/L tryptone, 5 g/L yeast extract, 
10 g/L NaCl) containing 100 μg/mL ampicillin from the pre-inoculation overnight culture at 
37 °C and 250 rpm. When the OD600nm was in the range of 0.6–1, 400 mL of the 
autoinduction medium in 2 L Erlenmeyer flasks was inoculated with 1% (v/v) of the 
inoculation culture. For the first 20 h, the cultivation was performed in the rotatory shaker at 
30 °C and 150 rpm in the presence of 100 μg/mL ampicillin, and then the temperature was 
lowered to 25 °C. The overall cultivation time was 70–72 h. The biomass was centrifuged 
(2750 g, 30 min, 4 °C), and the pellet was resuspended in 1/10th of the original volume in 
potassium phosphate buffer (0.1 M, pH 7.8) and centrifuged again. The biomass was stored at 
-20 °C until use. 
 
Cell lysates preparation 
2 mL of the fermentation broth of known OD600 were centrifuged (4942 g, 4 °C, 15 min). The 
pellet was re-suspended in 400 μL potassium phosphate buffer (0.1 M, pH 7.8) and the cell 
suspension was sonicated for 10 on/off cycles of 10 seconds at an amplitude of 10 μm using 
the Soniprep 150 sonicator (MSE, Sanyo, Japan). If a higher amount of lysate was required, 
the volumes were proportionally higher. The lysate was centrifuged (4942 g, 4 °C, 15 min) 
and the supernatant was used for further analysis. 
 
Biotransformation 
1,2,3,4-tetrahydroisoquinoline (THIQ, 95%, Sigma Aldrich) was selected as the model 
substrate for biological oxidation using MAO-N as a biocatalyst. Probably due to 
spontaneous oxidation, THIQ contains ~2.5% 3,4-dihydroisoquinoline (DHIQ), which was 
not taken into account in the calculations. To obtain 10 mL of the 100 mM substrate stock 
solution,  
131.4 µL THIQ was dissolved in 1.32 mL N,N-dimethylformamide (DMF) and MOPS buffer 
(0.1 M, pH 7.8), and the pH was adjusted to 7.8 with 85% phosphoric acid. The small scale 
biotransformation with either the whole cells or with the cell lysate was performed in 50 mL 
falcon tubes in a MOPS buffer (0.1 M, pH 7.8) at 37 °C and 250 rpm. For the whole cells, the 
concentration of the biocatalyst was 6.83 mg of the dry cell weight (mgDCW) per mL of 
reaction. The cell lysate was produced using the same amount of dry cell weight as was used 
for the whole cell biotransformation. If not stated otherwise, the total reaction volume was  
2.6 mL. The consumption of THIQ and the formation of DHIQ were monitored by HPLC 
analysis.  
For the determination of kinetic parameters, biotransformations with 2.3, 5.3, 10.8, 21.4, 
31.8, 41.8 and 48 mM THIQ were performed in duplicates following the above mentioned 
procedure and the initial reaction rates were calculated. The mean initial rates of the 
duplicates were calculated and plotted, with the error bars representing the standard 
deviation. Kinetic parameters Vmax and KM were calculated using the Prism 5 software 
(GraphPad Software, Inc., CA, USA). 
 
Optimization of the chemical step 
For the individual testing of the chemical reaction, separate from the biological step, 
commercially available 3,4-dihydroisoquinoline (DHIQ, 97.5%, Sigma Aldrich) was used as 
the substrate. To make 40 mM of the stock solution, 51.2 µL DHIQ was dissolved in 510 µL 
DMF and MOPS (0.1 M, pH 7.8) in a 10 mL volumetric flask. The reaction was performed in 
a 50 mL falcon tube at 37 °C and 250 rpm in 2 mL volume with 20 mM substrate in a MOPS 
buffer (0.1 M, pH 7.8). The 40 mM stock solution of CuI was prepared by dissolving 76 mg 
of CuI in 10 mL acetonitrile. To find the optimal ratio of CuI and H2O2, the following 
combinations were tested for the oxidation of DHIQ to the lactam 3,4-dihydroisoquinoline-
1(2H)-one (DHIO): 1 mol% CuI (10 µL of the stock solution, 0.0004 mmol) and 10 eq. H2O2 
(39 µL of the 35% solution, 0.4 mmol); 0.5 mol% CuI (5 µL of the stock solution,  
0.0002 mmol) and 10 eq. H2O2; 0.5 mol% CuI and 5 eq. H2O2 (19.5 µL of the 35% solution, 
0.2 mmol). The reactions were performed in duplicates, of which the mean and standard 
deviation were calculated and plotted. 
 
Stability studies 
To test the effect of chemocatalysts (CuI and H2O2) on the biocatalyst, stability studies were 
performed on both cells and lysates of MAO-N D9 and D11 variants. Four sets of reaction 
mixtures, each of total volume 3.36 mL, were set in 50 mL falcon tubes at 37 °C and 250 
rpm. Except for the MOPS buffer (0.1 M, pH 7.8) and the biocatalyst, one contained 1 mol% 
CuI (21 µL of 40 mM stock solution, 0.00084 mmol) and the other, 10 eq. H2O2 (81.9 µL of 
35% solution, 0.84 mmol), while the third contained a combination of 1 mol% CuI + 10 eq. 
H2O2, and the last one was left as a control without chemical factors. The amount of chemical 
agents was calculated for the volume sufficient for 3.5 reactions with 20 mM substrate. The 
concentration of the biocatalyst was equal for the whole cells and the cell lysate and 
accounted for 6.83 mgDCW per mL of reaction.  
1.2 mL standard biotransformations were performed with all setups containing CuI (1 mol%, 
0.00024 mmol), H2O2 (10 eq, 0.24 mmol) or both after two, four, and 24 h of incubation as 
follows: 960 μL of reaction mixture were taken from the stock and 240 μL of 100 mM THIQ 
stock were added to reach the 20 mM initial substrate concentration. The biotransformation 
with the control setup without CuI and H2O2 was performed at the beginning of the 
incubation (t = 0 h) and after 24 h. Samples taken after 3 h of the biotransformation were 
analyzed using HPLC.  
 
Intermediate product inhibition 
The MAO-N D9 cell stock was re-suspended in the MOPS buffer (0.1 M, pH 7.8) to reach a 
5x more concentrated suspension than what was required for the biotransformation  
(6.83 mgDCW/mL). The amine (THIQ) stock solution was prepared as mentioned above. 5 mL 
of 90 mM imine intermediate product (DHIQ) stock solution was prepared by dissolving  
57.6 µL DHIQ in 580 µL DMF and the MOPS buffer (0.1 M, pH 7.8). Prior to starting the 
biotransformation with 20 mM THIQ, the cell suspension in MOPS was incubated in 50 mL 
falcon tubes for 15 min with the particular amount of imine to reach 10, 20, 30 and 40 mM 
final concentration in 2.6 mL total volume of the reaction mixture. By adding the substrate, 
the biomass concentration was adjusted to 6.83 mgDCW/mL and standard biotransformations 
in duplicates were performed at 37 °C and 250 rpm. The mean values of the initial rates were 
calculated and plotted, with the error bars representing standard deviations. 
 
One-pot two step reaction scale-up 
The reaction setup (Error! Reference source not found.) was scaled-up to an initial volume 
of 25 mL and was performed in 250 mL baffled shake flasks at 37 °C and 250 rpm. The 
MAO-N D9 cell stock was re-suspended in the MOPS buffer (0.1 M, pH 7.8) to reach 5x 
concentrated suspension, which was further diluted by adding MOPS and a portion of the 100 
mM THIQ stock. The biological step was started with a 25 mL reaction volume at standard 
conditions (biomass concentration 6.83 mgDCW/mL, 20 mM THIQ). After three, six and nine 
hours, the reaction mixture was supplemented with an amount of 100 mM THIQ stock 
needed to reach 20 mM, taking into account the increasing reaction volume, irrespective of 
the remaining substrate from the previous feeding. At each substrate feeding point, the 
reaction mixture was supplemented with an adequate portion of cells (gDCW) corresponding to 
the amount that was taken out during the sampling in order to keep the amount (not the 
concentration) of the biocatalyst constant. The reaction was monitored over time and after 25 
h, the shake flasks were removed from the shaker and stored at 4 °C overnight. Taking into 
account the volume of the chemical agents, a portion of the reaction mixture was removed 
and the chemical step was started with 45 mM biologically produced DHIQ, 1 mol% CuI 
(11.25 µL/mLreaction) and 10 eq. H2O2 (43.9 µL/mLreaction). The reaction ran for 24 h and was 
monitored by HPLC. 
Insert Figure 1. 
Analytical method 
150 μL samples were taken from the reaction mixture. The reaction was quenched by adding 
150 μL 0.5% (v/v) trifluoracetic acid (TFA), followed by intensive vortexing and 
centrifugation (16060 g, 10 min). The samples were diluted with the aqueous mobile phase so 
that the concentration of each of the analyzed substances was in the range of their calibration 
curves. Both the biological and chemical reaction steps were monitored via HPLC using the 
Dionex Ultimate 3000 system equipped with the Ultimate 3000 pump, an autosampler, a UM 
3000 RS variable wavelength detector, and an ACE 5 C18 column (150 mm × 4.6 mm, 5 µm 
particle size; Advance Chromatography Technologies, Aberdeen, UK). MilliQ water and 
methanol, both containing 0.1% TFA (v/v), were used as mobile phases. The gradient 
analysis was performed according to the conditions in Error! Not a valid bookmark self-
reference. at 30 °C at a constant flow rate of 1 mL/min. The injection volume was 20 µL and 
the analytes were detected at 260 nm. The quantitative analysis was performed by integration 
of peak areas using the external standard method. DHIO standard (98%) was purchased from 
NovoChemy Ltd. (Shanghai, China). The THIQ, DHIQ and DHIO retention times were 7.1 
min, 4.2 min and 13.3 min respectively. 
Insert Table I. 
 
RESULTS AND DISCUSSION 
 
Selection of the expression strain 
MAO-N variants have previously been expressed both in BL21(DE3) (Bechi et al. 2014; 
Ghislieri et al. 2013a; Köhler et al. 2010) and C43(DE3) cells (Ghislieri et al. 2013b; Heath et 
al. 2016; Schrittwieser et al. 2014). The preliminary studies focused on the selection of the 
host strain for the highest MAO-N D9 and MAO-N D11 expression. Based on the SDS-
PAGE analysis, no obvious overexpression of MAO was observed in Lemo21(DE3) and 
BL21(DE3) Gold strains cultivated according to the manufacturers´ instructions, nor in the 
autoinduction medium (data not shown). Both the whole cells and the crude cell lysate of 
Lemo21(DE3) strain showed almost no activity towards THIQ. Although there was some 
MAO-N D9 expression in BL21(DE3) Gold strain (MAO-N D11 was not tested) cultivated in 
the autoinduction medium, as confirmed by the conversion of THIQ to DHIQ, it was not 
satisfactory. Only about 41% and 30% yield was reached after 23 h of 20 mM THIQ 
biotransformation, performed with cells cultivated for 71 h and the corresponding lysate, 
respectively. Much better performance in terms of DHIQ yield was observed with the E. coli 
OverExpress C43(DE3) strain cultivated in the autoinduction medium. Three sets of samples 
were taken at 21, 46 and 72 h of cultivation. To choose the best biocatalyst for further 
experiments, biotransformation of 20 mM THIQ in 2.9 mL of the total reaction volume was 
performed with both MAO-N D9 and D11 cells and lysates. After 3 h of biotransformation, 
the DHIQ yield shows a difference between the two forms of the biocatalyst (whole cells, cell 
lysate), as well as the effect of the length of cultivation on MAO expression (Figure 10). The 
highest imine yield, ~91% (cells) and ~94% (lysate), was obtained with MAO-N D9 that had 
been expressed for 72 h. 
Insert Figure 2. 
Although there is only a single point mutation between MAO-N variants D9 and D11, there 
are significant differences in the performance between them, leading to the selection of the 
D9 variant for further studies on this reaction model. Moreover, the results obtained with the 
whole cells and lysate of MAO-N D9 variant are similar. As the difference between the 
amount of DHIQ obtained with MAO-N D9 expressed for 46 and 72 h are just very slight, 
additional information was needed to determine the suitable length of cultivation. Samples 
for OD600nm and the protein analysis were taken in several stages of growth, at which the dry 
cell weight was also calculated. The difference in this parameter in terms of biomass yield 
(3.91 ±0.07 gDCW/L at 46 h and 4.89 ±0.30 gDCW/L at 72 h) was decisive for the cultivation 
time to be 72 h. The increase in MAO-N D9 expression over time was also proven by SDS-
PAGE (Figure 11). 
Insert Figure 3. 
Considering the costs of biocatalyst production in terms of process scale-up, the aim is to 
minimize the enzyme purification and operate the process with the crudest form of catalyst 
possible (Pollard and Woodley 2007). Although almost the same amount of DHIQ was 
obtained with MAO-N D9 cells and lysate during each stage of cultivation (Figure 10), in 
order to keep the process simple and avoid the number of procedures, MAO-N D9, in the 
form of whole cells harvested after 72 h, was selected as a biocatalyst for further use.  
 
The effect of CuI/H2O2 on the biocatalyst 
The decision for MAO-N D9 cells to be the biocatalyst of choice for the combination with the 
chemocatalytic step was also supported by stability studies in the presence of CuI/H2O2 
performed on the first reaction step of Error! Reference source not found.. Bechi et al. 
(2014) used pure MAO-N D9 for the one-pot two-step cascade conversion of cyclic amine 
(THIQ) to lactam (DHIO). However, no lactam formation was observed when MAO-N D9 
whole cells and cell lysate were used for this model chemo-biotransformation, in combination 
with CuI/H2O2, when all the reagents were mixed in one-pot at the beginning of the reaction. 
Therefore, the investigation of the effect of CuI, H2O2 and their combination on the MAO-N 
D9 cells and cell lysate was performed. After 2, 4 and 24 h of incubation of the biocatalyst 
with CuI, CuI + H2O2 and H2O2, standard biotransformation with 20 mM THIQ was 
performed. For comparison, control biotransformations were run with the cells and the lysate 
at t = 0 h and after 24 h of incubation at 37 °C and 250 rpm. Samples were taken after 3 h of 
biotransformation and the amount of formed imine was compared (Figure 12). While the 
incubation in the presence of 10 eq. H2O2 had almost no effect on the amount of formed 
imine by MAO-N D9 cells, it was lowered by half in the presence of 1 mol% CuI. In both 
cases, the contact time did not play a significant role and almost the same amount of imine 
was formed after 2 and 24 h of incubation (Figure 12A), indicating that CuI probably causes 
deactivation of the biocatalyst in less than 2 h. The combination of 1 mol% CuI and 10 eq. 
H2O2 had the most harmful effect on MAO-N D9 cells, and only 4.6 mM DHIQ was formed 
after 2 h incubation. In contrast to the cells, not more than 1.2 mM DHIQ was reached with 
MAO-N D9 lysate that was previously incubated with the chemical agents (Figure 12B), 
excluding the lysate from further studies. As shown above, MAO-N D9 is sensitive to CuI 
and H2O2. Unlike the cell lysate, cell membranes of the intact whole cells protect the 
intracellular enzyme and diminish the negative impact of the chemicals. 
Insert Figure 4. 
 
The ratio of CuI and H2O2 
When pure MAO-N D9 was used as a biocatalyst in the reaction (Fig. 1), only the amount of 
H2O2 was optimized and the best results were reached with 10 eq. (Bechi et al. 2014). Unlike 
CuI, H2O2 itself does not negatively affect the activity of MAO-N D9 cells, even after 24 h 
incubation. It is obvious that the combination of CuI and H2O2 is very harmful for the 
biocatalyst, even at 2 h of contact (Figure 12.Figure 12A). Three combinations of CuI and 
H2O2 were tested in order to find their optimal ratio and possibly lower the amount for the 
transformation of  
20 mM commercially available DHIQ to lactam (DHIO), which is the desired final product. 
The reaction was performed in duplicates in 50 mL falcon tubes with a 2 mL total reaction 
volume and was monitored over time. The highest concentration of DHIO was reached when 
1 mol% CuI and 10 eq. H2O2 were used (Figure 13). 
Insert Figure 5. 
After 25 h of reaction, the concentration of formed DHIO did not significantly increase 
compared to 4 h, and reached 13.5 ±3.6 mM (1 mol% CuI + 10 eq. H2O2), 7.8 ±0.1 mM  
(0.5 mol% CuI + 10 eq. H2O2), and 6.4 ±0.2 mM (0.5 mol% CuI + 0.5 eq. H2O2). Despite the 
negative effect of the chemical agents on the biocatalyst, in order to keep the reaction 
effective, it was not possible to lower their amount, as the best results were reached with 
1 mol% CuI and 10 eq. H2O2.  
 
Kinetic parameters determination of MAO-N D9 cells 
As MAO-N D9 is a relatively new variant of monoamine oxidase (Rowles et al. 2012), so far 
only one kinetic study has been performed with the pure enzyme in the one-pot 
deracemization of the alkaloid (±)-crispine A (Rowles et al. 2012). In our study, E. coli 
OverExpress C43(DE3) cells expressing MAO-N D9 were selected as the biocatalyst to be 
used in the one-pot two-step conversion of cyclic amine to lactam. The initial rates were 
calculated for the standard biotransformations with a THIQ concentration in the range of 2.3–
48.0 mM, representing the amount of formed DHIQ per unit time. The results were plotted 
(Figure 14) and analysed using the Prism 5 software (GraphPad Software, Inc., CA, USA), 
and fitted well the Michaelis–Menten model with the following kinetic parameters:  
Vmax = 36.58 mM/h and KM = 8.124 mM (R2 = 0.9843).  
Insert Figure 6. 
Rios-Solis et al. (2015) used the advantage of a microscale high throughput screening 
platform to screen the substrate specificity and kinetic parameters for the MAO-N variant D5 
towards various secondary amines. The obtained KM values were of the same order of 
magnitude as our result. Generally speaking, the amine inhibition is the main factor affecting 
the overall reaction rate and for the purpose of the reaction scale-up it has been suggested to 
fed-batch the amine substrate. Similar behavior is assumed for the MAO-N D9. 
 
Intermediate product (DHIQ) inhibition  
Previous studies performed with the MAO-N variant D5 indicate that the forming cyclic 
imine product causes inhibition and inactivation of the biocatalyst (Ramesh and Woodley 
2014), although the imine inhibition constants are 1-2 orders of magnitude higher than the 
corresponding substrate inhibition constants (Rios-Solis et al. 2015). Another example of 
irreversible imine inhibition was observed during boceprevir synthesis using the MAON401 
variant, after 0.8 mM imine already caused a 40% decrease of activity over time. The 
inhibition issues were overcome by optimizing the substrate feeding and addition of bisulfite 
to achieve a trapping of the imine product (Kohls et al. 2014; Li et al. 2012). It was assumed 
that imine inhibition might also be the reason why the model reaction could not be performed 
with whole cells as a one-pot two-step cascade with all the reagents mixed from the 
beginning of the reaction, as it was possible with the pure enzyme in the study of Bechi et al. 
(2014). Therefore, an inhibition study using commercially available imine DHIQ was 
performed. The biocatalyst was incubated in the presence of DHIQ (11.0, 21.7, 31.8 and 42.5 
mM) for 15 min prior to starting the standard biotransformation with 20 mM THIQ. The 
effect of imine on the biological step of the model reaction was expressed as a relative initial 
rate compared to the control experiment performed without the addition of DHIQ to the 
reaction, corresponding to a 100% initial rate. The results prove that the intermediate imine 
product has an inhibitory effect on MAO-N D9, even at low concentrations and after a short 
contact time, resulting in an almost 50% decrease of the initial rate at 21.7 mM DHIQ and 
more than a 70% decrease at 42.5 mM DHIQ (Figure 15).   
Insert Figure 7. 
 
One-pot two-step chemo-biocatalyzed reaction 
As mentioned before, the direct conversion of amine to lactam via one-pot chemo-
biocatalysis is not possible when MAO-N D9 whole cells are used, and it is necessary to 
perform the reactions stepwise. The biotransformation step with 20 mM THIQ as a substrate 
was scaled-up to 250 mL baffled shake flasks and the reaction was started with an initial 
volume of 25 mL and biomass concentration 6.83 mgDCW/mL. In order to shorten the contact 
time of the biocatalyst with high substrate concentration and following the recommendation 
of Rios-Solis et al. (2015) to avoid amine inhibition, feeding strategy was applied during the 
production of DHIQ. Triple feeding with 20 mM THIQ was performed three, six and nine 
hours from the start, while the amount of biocatalyst was kept constant by adding the amount 
of cells that was taken out during the sampling, accounting for 6%, 4.5%, and 3.8%, 
respectively. The feeding intervals and the amount of added substrate was a compromise 
between the empirical knowledge about the length of the biotransformation with fresh 
biocatalyst (~3 h), the already known inhibition effect of DHIQ and the aim to effectively and 
conveniently produce as much DHIQ as possible. After 25 h of biotransformation, the 
concentration of DHIQ reached 48.2 mM and the overall yield was 71.3% ( 
A). The overall yield was calculated as the ratio of micromoles of produced DHIQ to the total 
amount of micromoles of added THIQ. 
Insert Figure 8. 
Following the biological production of DHIQ, its chemical conversion to DHIO was 
employed as a second step in the one-pot system by adding 1 mol% CuI and 10 eq. H2O2 
without removing the biocatalyst (Fig. 8B). The amount of chemical reagents was calculated 
to correspond to 45 mM imine. This step was performed in the same parallel reaction vessels 
in which DHIQ was produced. The reaction was monitored for 25 h and the results indicate 
that more than 70% of DHIO was formed in the first five hours, to reach a final concentration 
of ~30 mM after 25 h (Error! Reference source not found.). The residual THIQ from the 
first step remains unaffected in the mixture, and therefore was not involved in the overall 
yield. This was calculated as the ratio of micromoles of formed DHIO to micromoles of 
initial DHIQ in the mixture, accounting for 69.4%.  
Bechi et al. (2014) reached 69% conversion of 40 mM THIQ to DHIO in a one-pot two-step 
reaction, employing 0.4 mg/mL pure MAO-N D9, where all of the reactants were mixed 
together from the beginning of the process. In our case, when MAO-N D9 cells were used, 
although still performed in one-pot, it was necessary to separate the bio- and chemocatalytical 
step due to intermediate product inhibition of the biocatalyst and its instability in the presence 
of the chemical catalysts. Therefore, it would be misleading to express the conversion 
directly from THIQ. As Bechi et al. (2014) demonstrated, the same lactam product could be 
produced in 94% conversion by also coupling pure MAO-N D9 with E. coli expressing 
xanthine dehydrogenase. Compared to the previous study, we scaled-up the reaction and 
modified the analytical method, which has allowed simplification of the sample work up by 
omitting the extraction step to DMC followed by drying. During the chemical step of the 
reaction, a loss of cell integrity was observed, as there was almost no pellet present in the 
samples taken after a couple of hours of reaction and their work up. Despite the 
inhibition/inactivation effect of the chemical agents, the advantage of this model reaction is 
the compatibility of reaction conditions for both steps, which are performed at a mild 
temperature and pH in a buffer aqueous environment. This is more typical for concurrent 
one-pot chemoenzymatic processes (Denard et al. 2013). 
Despite the different nature of bio- and chemocatalysts, there are ways that they complement 
each other and work in similar conditions. There is no general model or prediction for the 
interactions between chemical catalysts and enzymes, as they depend individually on the 
characteristics of the two catalysts, as well as of the reaction being catalyzed (Denard et al. 
2013). When it comes to compatibility issues, compartmentalization is one of the ways to 
minimize the mutual toxic interactions of the bio- and chemocatalyst. One of the options is to 
separate them in different liquid phases (e.g. ionic liquids) or to isolate them by supporting on 
organic or inorganic solid-state materials (Marr and Liu 2011). In the latter case, their 
reusability might be achieved. Although a chemical catalyst was not involved, in a recent 
study, we proved that when immobilized, MAO-N whole cells could be repeatedly used for 
the biotransformation of the model secondary amine (Zajkoska et al. 2015).  
Coupling of bio- and chemocatalyzed reactions opens new horizons in the synthesis of 
valuable intermediates and recent studies have proven that MAO-N is a very suitable and 
perspective experimental model to be used in cascade reactions. One of the most recent 
works involved MAO-N whole cells in bio-chemo-bio one-pot transformation of rac-
benzylisoquinolines to (S)-berbines. The (R)-selective MAO-N D11 variant was cascade-
combined with morpholine BH3 (acting as non-selective reducing agent) and berberine bridge 
enzyme (catalyzing the (S)-enantioselective C–C bond formation) as an example of how two 
flavin-dependant oxidases of opposite enantioselectivity, acting on different parts of the 
benzylisoquinoline substrate, could be combined in one-pot (Schrittwieser et al. 2014). A 
novel combination of two important amine synthesis biocatalysts – transaminases and MAO-
N variants – was used under compatible conditions for the regio- and stereoselective 
synthesis of chiral 2,5-disubstituted pyrrolidine building blocks, as well as for the 
deracemization and dealkylation of a range of methylbenzylamine derivatives. Taking into 
account the broad substrate specificity of MAO-N variants, there are examples of one-pot 
chemo-biocatalytic cascades involving transaminase, MAO-N and a non-selective reducing 
agent (O'Reilly et al. 2014a; O'Reilly et al. 2014b; O'Reilly and Turner 2015). In addition to 
the conventional one-pot processes, engineered biometallic E. coli cells combining nanoscale 
bioreduced Pd(0) particles and a MAO-N D5 variant in a single organism were used to for the 
deracemization of 1-methyltetrahydroisoquinoline (MTQ) to (R)-MTQ via an imine 
intermediate. The two reactions were performed separately in one vessel using hydrogen as 
an electron donor in the reduction step (Foulkes et al. 2011). This is a novel approach to 
using synthetic biology tools in the development of organisms for multistep chemo-
biocatalyzed one-pot reactions involving not only MAO.  
 
Conclusion 
In this study, we demonstrated a one-pot two-step conversion of cyclic amine to lactam 
employing whole cells that express MAO-N coupled with a Cu-based oxidative system. 
Taking into account that MAO-N variants have an affinity towards a variety of amine 
substrates, this proves the concept that the whole cell biocatalyst can be competitive with a 
pure enzyme and advantageous in terms of scale-up. Compared to pure enzymes, several 
operational steps are omitted in the production of the biocatalyst.  
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Table I. Mobile phase gradient for the quantification of THIQ, DHIQ and DHIO 
 
t (min) MilliQ + 0.1% TFA MeOH + 0.1% TFA 
0 - 10 85 15 
10-10.5 30 70 
10.5-15.5 20 80 
15.5-16 0 100 
16 - 18 0 100 
18-18.5 85 15 
18.5 – 20.5 85 15 
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Figure 1. One-pot two-step chemo-biocatalytic conversion of 1,2,3,4-tetrahydroisoquinoline 
(THIQ) to 3,4-dihydroisoquinolin-1(2H)-one (DHIO) via imine (DHIQ) intermediate. 
Figure 2 Imine (DHIQ) formed from 20 mM THIQ at t = 3h by MAO-N D9 and MAO-N 
D11 in form of E. coli OverExpress C43(DE3) cells and lysate from the equal amount of cells 
harvested at 21 (white bars), 46 (grey bars) and 72 (black bars) hours of cultivation. 
Figure 3. SDS-PAGE of E. coli OverExpress C43(DE3) expressing MAO-N D9 (55 kDa) 
cultivated in autoinduction media over time. Lanes: molecular weight standard (1);7.5 h (2); 
21 h (3); 26 h (4); 31 h (5); 46 h (6); 54.5 h(7); 72 h (8). 
Figure 4. The effect of 1 mol% CuI, 10 eq. H2O2 and their combination on MAO-N D9 cells 
(A) and lysate (B) after 0, 2, 4 and 24 h incubation. The results represent the amount of 
formed imine (DHIQ) after 3 h biotransformation of 20 mM THIQ at 37 °C and 250 rpm. 
Figure 5. Chemotransformation of 20 mM DHIQ to DHIO using different ratios of CuI and 
H2O2.  
Figure 6. Kinetic performance of MAO-N D9 expressed in E. coli OverExpress C43(DE3) 
cells.  
Figure 7. The inhibition effect of 3,4-dihydroisoquinoline (DHIQ) on the biotransformation 
with 20 mM THIQ.  
Figure 8. Two-step chemo-biocatalysis in a one-pot system: Triple substrate feeding during 
the biological step with initial reaction volume of 25 ml and an initial biomass concentration 
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